What this study is
This study evaluates the Chilipad Dock Pro Bed Cooling System and Sleep Tracker, examining how bed temperature influences sleep quality and overall well-being.
What's being tested
- Chilipad Dock Pro Bed Cooling System and Sleep Tracker
Intervention · DEVICE
The Chilipad Dock Pro Bundle is an advanced sleep system designed to optimize sleep by dynamically adjusting the bed's surface temperature. It consists of a thermoregulated mattress pad and a Dock Pro control unit that actively circulates water through the pad, allowing users to customize the temperature between 55°F and 115°F. The system offers both single and dual control, making it ideal for individual or shared use. Equipped with AI-driven features, the Dock Pro can monitor sleep patterns and environmental factors to make real-time adjustments, ensuring optimal sleep conditions throughout the night. This intelligent temperature management system is only enhanced when paired with the optional Sleepme Tracker, creating a personalized sleep experience.
Study details
- Sponsor
- Efforia, Inc
- Conditions
- Sleep
- Enrolling
- 100 people
- Starts
- 2025-09-25
- Est. completion
- 2026-09-25
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers AcceptedYou may qualify if
- Can read and understand English.
- US resident.
- Willing and able to follow the requirements of the protocol.
You can't join if
- Individuals with concerns about water leakage.
- Individuals with sleep disorders related to changes in temperature
- Individuals with thermal sensitivity
- Individuals who are easily frustrated by technology.
- Individuals with pacemakers or medical implants sensitive to electromagnetic fields
- Pregnant individuals
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 open- Recruiting
Study team
Sponsor
Efforia, Inc
Study ID 13228
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.